Callisto Pharmaceuticals Files Provisional Patent Applications on Antiangiogenic Activity of Atiprimod.Business Editors/Health/Medical Writers NEW YORK--(BUSINESS WIRE)--July 21, 2003 Callisto Pharmaceuticals, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : CLSP CLSP Center for Language and Speech Processing CLSP Cisco Learning Solutions Partner CLSP Channel Load Sensing Protocol CLSP Community Legal Services Program CLSP Clinical Laboratory Sciences Program CLSP Center for Law and Social Policy ) announced that it has filed two provisional patent applications covering the antiangiogenic an·ti·an·gi·o·gen·ic adj. Inhibiting the growth of blood vessels. antiangiogenic properties of Atiprimod and azaspirane analogs. The antiangiogenic and anticancer activities of Atiprimod are being further evaluated under a Screening Agreement with the National Cancer Institute to evaluate Atiprimod in solid tumor animal models. Callisto is a biopharmaceutical company focused on the development of drugs to treat multiple myeloma, other cancers and osteolytic osteolytic adjective Causing bone breakdown bone disease. Callisto's lead drug candidate, Atiprimod, is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. Atiprimod successfully completed Phase I clinical trials in rheumatoid arthritis patients and Callisto plans to enter Atiprimod in a safety and proof-of-principle clinical trial in multiple myeloma patients. Callisto intends to submit to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. by August 2003 an IND to treat multiple myeloma patients. The drug is also being explored as an agent to treat osteolytic bone disease. In addition, Callisto has programs focused on the development of an analog of the human intestinal hormone, uroguanylin, to treat colon cancer, and drugs to protect against staphylococcal and streptococcal streptococcal /strep·to·coc·cal/ (-kok´al) pertaining to or caused by a streptococcus. Streptococcal (Streptococcus) Pertaining to any of the Streptococcus bacteria. bioweapons, as a protection against the devastating effects of toxic shock syndrome toxic shock syndrome (TSS). acute, sometimes fatal, disease characterized by high fever, nausea, diarrhea, lethargy, blotchy rash, and sudden drop in blood pressure. It is caused by Staphylococcus aureus, an exotoxin-producing bacteria (see toxin). . Callisto has two operating subsidiaries, Callisto Research Labs, LLC and Synergy Pharmaceuticals Inc. Included in this release are "forward-looking: statements. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. Callisto's actual results could differ materially from those anticipated in the forward-looking statements as a result of various factors. --30--RC/
CONTACT: For Callisto Pharmaceuticals, Inc.
Gary S. Jacob, 732-302-1111
KEYWORD: NEW YORK
INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Callisto Pharmaceuticals, Inc.
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion